Vaxart Inc.

0.39
0.04 (11.43%)
At close: Apr 03, 2025, 3:59 PM
0.38
-1.94%
Pre-market: Apr 04, 2025, 04:05 AM EDT

Company Description

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform.

The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection.

It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus.

The company is headquartered in South San Francisco, California.

Vaxart Inc.
Vaxart Inc. logo
Country United States
IPO Date Dec 11, 1981
Industry Biotechnology
Sector Healthcare
Employees 105
CEO Steven Lo

Contact Details

Address:
170 Harbor Way
South San Francisco, California
United States
Website https://vaxart.com

Stock Details

Ticker Symbol VXRT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000072444
CUSIP Number 92243A200
ISIN Number US92243A2006
Employer ID 59-1212264
SIC Code 2836

Key Executives

Name Position
Steven Lo President, Chief Executive Officer & Director
Dr. Raymond D. Stapleton Jr., Ph.D. Chief Technology Officer
Phillip Eric Lee Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer
Dr. James F. Cummings M.D. Chief Medical Officer
Dr. Rajesh Kapoor Ph.D. Senior Vice President of Quality
Dr. Sean N. Tucker Ph.D. Senior Vice President & Chief Scientific Officer
Edward B. Berg Senior Vice President & General Counsel
Laurie Hastings Senior Vice President of Human Resources
Shaily Jaini Garg Senior Vice President of Clinical Development & Project Management

Latest SEC Filings

Date Type Title
Apr 01, 2025 4 Filing
Apr 01, 2025 4 Filing
Mar 31, 2025 PRE 14A Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 26, 2025 4 Filing
Mar 21, 2025 8-K Current Report
Mar 21, 2025 424B5 Filing